<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">Here, we describe the design and the rationale of PRIME-HCC, a two-part multi-centre phase Ib study to assess safety and bioactivity of the nivolumab and ipilimumab combination before LR in patients with HCC.</p>
